Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

Journal of Neuro-Oncology

Volumn 99, Issue 2, 2010, Pages 237-242

  Zuniga, Richard M ^a   Torcuator, Roy ^a   Jain, Rajan ^a   Anderson, John ^a   Doyle, Thomas ^a   Schultz, Lonni ^a   Mikkelsen, Tom ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Bevacizumab; Glioblastoma; Glioma; Rebound; Recurrent glioma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EM 1421; ERLOTINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; RAPAMYCIN; TANDUTINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 77956061453     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0121-0     Document Type: Article

References (20)

1. R Stupp WP Mason MJ van den Brent M Weller B Fischer MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann R Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Esenhauer R Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009
2. ET Wong KR Hess MJ Gleason KA Jaeckle MD Prados VA Levin WK Yung 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D 10561324
3. N Ferrara 2005 VEGF as a therapeutic target in cancer Oncology 69 Suppl 3 11 16 10.1159/000088479 1:CAS:528:DC%2BD2MXht1aqsrnF 16301831
4. CR Pradeep ES Sunila G Kuttan 2005 Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies Integr Cancer Ther 4 315 321 10.1177/1534735405282557 1:CAS:528: DC%2BD2MXhtlaisLvE 16282508
5. O Kargiotis JS Rao AP Kyritsis 2006 Mechanism of angiogenesis in gliomas J Neurooncol 78 281 283 10.1007/s11060-005-9097-6 1:CAS:528:DC%2BD28Xpt1ylt7Y%3D 16554966
6. RT-P Poon S-T Fan J Wong 2001 Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 1207 1225 1:CAS:528:DC%2BD3MXhvFertrc%3D 11181687
7. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D 12890841
8. H Hurwitz L Fehrenbacker W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435
9. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer N Engl J Med 355 2542 2550 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI 17167137
10. KD Miller M Wang J Gralow M Dickler MA Cobleigh EA Perez TN Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
11. JJ Vredenburgh A Desjardins JE Herndon JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 10.1158/1078-0432.CCR-06-2309 1:CAS:528: DC%2BD2sXhvF2htr8%3D 17317837
12. Cloughesy T, Prados M, Wen P, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent, treatment-refractory glioblastoma. J Clin Oncol, ASCO Annual meeting proceedings (Post-meeting edn), vol 26, no 15S (May 20 Suppl), 2010b
13. RM Zuniga R Torcuator R Jain J Anderson T Doyle S Ellika L Schultz T Mikkelsen 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 329 336 10.1007/s11060-008-9718-y 1:CAS:528:DC%2BD1MXjvFemtQ%3D%3D 18953493
14. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 10.1212/01.wnl.0000304121.57857.38 1:CAS:528:DC%2BD1cXitlyqs7o%3D 18316689
15. R Torcuator RM Zuniga T Doyle J Anderson T Mikkelsen, et al. 2008 Salvage concurrent chemotherapy with bevacizumab for recurrent malignant gliomas previously treated with bevacizumab and irinotecan Neuro-oncology 10 5 829 10.1215/15228517-2008-051 (abstract)
16. MR Mancuso R Davis SM Norberg S O'Brien B Sennino T Nakahara V Yao T Inai P Brooks B Freimark DR Shalinsky D Hu-Lowe DM McDonald 2006 Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2610 2621 10.1172/JCI24612 1:CAS:528:DC%2BD28XhtVKgu7rO 17016557
17. DR MacDonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
18. W Cacheux T Boisserie L Staudacher O Vignaux B Dousset O Soubrane B Terris C Mateus S Chaussade F Goldwasser 2008 Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery Ann Oncol 19 1651 1661 10.1093/annonc/mdn540
19. Y Matsumoto F Freund E Peiretti MJ Cooney D Ferrara LA Yannuzzi 2007 Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease Retina 27 426 431 10.1097/IAE.0b013e31804a7af2 17420693
20. S Ananthnarayan J Bahng J Roring P Nghiemphu A Lai T Cloughesy W Pope 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neuro-oncol 88 339 347 10.1007/s11060-008-9573-x